Sareum Holdings plc

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company generates value through licensing its candidates to pharma and biotech companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual TYK2 / JAK1 inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801), including the cytokine storm reaction to Covid-19 and other viral infections, and cancer immunotherapy (SDC-1802). The Company is targeting completion of preclinical development for each molecule in 2020.
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Chk1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary clinical and preclinical data suggest SRA737 may have broad applications in combination with other oncology and immuno-oncology drugs.
Ticker:
SAR.L
Exchange:
LSE AIM
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2004
Main Therapeutic Focus:
Lead Product in Development:
SDC-1801
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
CEO
Sareum